This page is educational and is not medical advice. It explains what the enzyme does, how typical and optimal ranges differ, what high and low results may reflect, and which markers are worth reading alongside it.
It measures the concentration of alanine aminotransferase circulating in your blood serum, reported in units per litre (U/L). Inside cells, the enzyme catalyses a reversible amino group transfer between alanine and alpha-ketoglutarate, producing pyruvate and glutamate. That reaction sits at the junction of protein and glucose metabolism, which is why the enzyme is so abundant in tissues that handle both.
The highest concentrations by far are in hepatocytes, the working cells of the liver, where the enzyme lives in the cytosol rather than locked inside mitochondria. Smaller amounts exist in skeletal muscle, kidney, heart and fat tissue. Two gene products are recognised, commonly described as ALT1 and ALT2, with different tissue distributions, and the enzyme requires vitamin B6 in its active form, pyridoxal 5-phosphate, as a cofactor[1].
Because the enzyme normally stays inside cells, serum levels are low in health. When a liver cell membrane becomes leaky, or the cell dies, the contents spill into the bloodstream and the measured value rises. That is the whole mechanism. The test is not measuring liver function in the sense of how well the organ is doing its job. It is measuring cellular leakage, which is a different and earlier signal.
Because the enzyme was renamed, and the old name stuck on lab reports. It was originally called serum glutamic pyruvic transaminase, abbreviated SGPT, after the substrates involved in the reaction. International enzyme nomenclature later standardised the name to alanine aminotransferase, abbreviated ALT.
There is no difference in what is measured, no conversion factor, and no difference in units. If one report says SGPT 22 U/L and another says ALT 22 U/L, they are the same finding. The same history applies to its partner enzyme, once called serum glutamic oxaloacetic transaminase (SGOT) and now called aspartate aminotransferase (AST).
Which label you see usually depends on the laboratory, the age of the panel template and local convention. Many labs now print both, for example ALT (SGPT), precisely so that readers comparing an old report with a new one do not think a new test has been added.
Related: When to Worry About ALT Levels (Liver Enzyme Guide)
It matters because it is one of the earliest and cheapest signals that the liver is carrying a metabolic load, often long before symptoms appear. Fat accumulating in liver cells is typically silent. The enzyme is one of the few routine markers that moves while that process is still quiet.
Research suggests the marker has predictive value rather than just descriptive value.[2][3] Studies have examined alanine aminotransferase as a risk marker for new-onset metabolic dysfunction-associated fatty liver disease[2], and a related analysis argued the old biomarker still earns its place because it is associated with incident steatotic liver disease of metabolic origin[3]. These are associations in populations, not predictions about any one person.
The practical point is that this enzyme behaves as a metabolic marker as much as a liver marker. It tends to track with visceral fat, insulin resistance and triglyceride handling. A value that drifts upward over years, even while staying inside the standard range, is information worth having. A value that is stable and low in the range is reassuring context, though it never rules anything out on its own.
A typical laboratory reference range for this enzyme runs roughly 7 to 56 U/L, while FitScript's optimal range is narrower.
| Marker | Typical lab reference range | FitScript optimal range |
|---|---|---|
| ALT (SGPT), serum | 7 to 56 U/L | 10 to 25 U/L |
Reference ranges vary by lab, age and sex, and the range printed on your own report is the one that applies to your sample. Optimal ranges are FitScript's optimization targets, not diagnostic cut-offs, and a value outside them is not a diagnosis.
Why the gap between the two columns is wide is worth understanding. Standard upper limits were historically derived from reference populations that included people with undiagnosed fatty liver and higher body weight, which pulls the statistical ceiling upward. Reviewers of the marker have discussed exactly this, and the case for interpreting it more tightly than legacy cut-offs imply[1]. Assay methods also differ, particularly whether the laboratory adds pyridoxal phosphate to the reaction, which can shift measured values between labs.
So a result of 45 U/L is inside most standard ranges and outside an optimization range. That is not a contradiction. It means the value is unlikely to represent overt disease, and it is still higher than where many people sit when metabolic load is low. The useful response is context and a repeat test, not alarm.
A higher result reflects liver cells releasing more enzyme than usual, and the size of the rise narrows the list of plausible explanations more than the rise itself does.
Mild elevations, broadly those a little above the reference ceiling, are common and are most often associated with metabolic fat accumulation in the liver, regular alcohol intake, recent medication or supplement exposure, or recent intense physical activity. Larger elevations, several times the upper limit, are associated with more acute hepatocellular injury, including viral hepatitis, certain drug reactions, autoimmune hepatitis and ischaemic injury. In chronic hepatitis C, for instance, acute exacerbations are described as enzyme flares, where the value can rise sharply during an episode[4].
Other patterns worth knowing about include iron overload, thyroid disorders, coeliac disease and inherited copper handling disorders. One analysis proposed alanine aminotransferase as a first test parameter when Wilson's disease is being considered in appropriate clinical settings[5]. None of that means any individual result points to any of these. A single value cannot identify a cause.
The sensible sequence is observation, then meaning, then next step. The observation is a number above your usual level. The possible meanings are many and overlapping. The next step is to repeat the test under clean conditions, run the companion markers that narrow the field, and discuss the pattern with a clinician who can see your history and medication list. A result outside the standard range should never be ignored, and a markedly elevated one is worth discussing with a clinician promptly.
Yes. The enzyme is liver-enriched, not liver-exclusive, and skeletal muscle is the most common non-hepatic source of a confusing result. Research in people with skeletal muscle diseases documented serum alanine aminotransferase elevations arising from muscle rather than liver, which is a recognised cause of unnecessary liver investigation[6].
Everyday versions of the same mechanism include an unaccustomed heavy resistance session, a long downhill run, or a return to training after a layoff. Significant muscle breakdown from extreme exertion, trauma or certain medications can raise the value substantially. Creatine kinase measured at the same time usually separates a muscle source from a liver source quickly.
Systemic illness also moves the number. In paediatric settings, studies have described the relationship between Kawasaki disease and alanine aminotransferase levels[7], and postoperative enzyme levels have been associated with outcomes in children undergoing total cavopulmonary connection surgery[8]. The common thread is that anything compromising perfusion or provoking a strong systemic inflammatory response can show up in this marker.
Finally, pre-analytical issues matter. A difficult blood draw causing haemolysis, a long delay before the sample is processed, or a different assay at a different lab can all shift a result without anything changing inside you.
A low result usually means little on its own, though very low values have attracted some interest. Most clinicians do not treat a value at the bottom of the range as abnormal, because the test was designed to detect leakage upward.
Two lines of thinking are worth knowing. First, since the enzyme depends on pyridoxal 5-phosphate as a cofactor, low vitamin B6 status can reduce measured activity in some assays, which is part of why laboratories differ on whether they add the cofactor to the reaction[1]. Second, because skeletal muscle contributes some circulating enzyme, persistently low values have been studied in relation to low muscle mass and frailty in older adults. These are observational associations and early signals, not conclusions about an individual.
In practice, a low value in a healthy, well-nourished, physically active person is not a problem to solve. A low value alongside unintended weight loss, low protein intake, declining strength or other out-of-range markers is context worth raising with a clinician rather than acting on alone.
More than most people expect, which is why one reading rarely settles anything. The main movers fall into a handful of groups.
None of these factors is a diagnosis. They are reasons to standardise the conditions of your next draw so the comparison is fair.
It is a standard venous blood draw, and fasting is not required for this marker specifically. The sample is spun to serum or plasma, and the laboratory measures enzyme activity with a coupled enzymatic reaction, tracking the consumption of NADH by absorbance. The number reported is enzyme activity, which is why units are U/L rather than a mass concentration.
Fasting still matters in practice because this enzyme is almost always drawn inside a wider panel. A liver panel usually includes AST, alkaline phosphatase, gamma-glutamyl transferase, bilirubin, total protein and albumin. A comprehensive metabolic panel adds glucose, electrolytes and kidney markers. If glucose, insulin or triglycerides are on the same requisition, follow the fasting instruction for those tests.
Method differences between laboratories are real and under-appreciated. Whether pyridoxal phosphate is added, which calibration is used and which instrument platform runs the sample can all shift results modestly, so comparing values across labs is less reliable than comparing within one. Measurement technology continues to develop, including research into electrochemical sensors built on graphene composite nanomaterials for detecting this enzyme[9], though routine clinical testing remains enzymatic.
As a trend, because a single value carries real measurement and biological noise. The most informative version of this marker is three or four results taken under similar conditions across a year, not one result taken after a weekend of heavy training and two drinks.
A practical approach is to standardise the draw. Use the same laboratory where possible, avoid unaccustomed heavy exercise for several days beforehand, keep alcohol out of the preceding days, note any new medication or supplement, and record the conditions alongside the number. If a value comes back unexpectedly high, a repeat after a few weeks under clean conditions is usually more informative than immediate extensive testing, unless symptoms or the size of the elevation suggest otherwise, in which case prompt clinical review comes first.
This is the logic behind repeated panel testing rather than one-off screening. FitScript builds its membership around 150+ biomarkers tested per year, with Atlas, FitScript's AI health advisor, interpreting how markers such as this one move together over time, and with any treatment decision made by a licensed provider after reviewing the member.
It adds a clue about the likely source and pattern of injury, without identifying a cause. Both enzymes rise with hepatocellular stress, but they are distributed differently. Alanine aminotransferase is more liver-specific, while aspartate aminotransferase is abundant in muscle, heart and red blood cells as well, and a substantial share of it sits inside mitochondria.
Clinicians have used the ratio between the two, sometimes called the De Ritis ratio, for decades as a pattern recognition tool. Broadly, a ratio weighted toward the alanine enzyme is the common pattern in metabolic fat accumulation, while a ratio weighted toward the aspartate enzyme is more often seen with alcohol-related injury, with advancing fibrosis, or when muscle is contributing. Those are tendencies described in the literature, not rules, and the ratio is never interpreted alone.
What the ratio really earns its keep for is prompting the right follow-up question. If the aspartate enzyme is disproportionately high, creatine kinase helps establish whether muscle is the source. If both are modestly raised alongside high triglycerides and a raised waist measurement, the metabolic picture is the one worth exploring with a clinician.
The ones that separate liver cell injury from bile flow problems, and liver signals from metabolic ones. On its own this enzyme is sensitive but not specific. In a panel it becomes interpretable.
| Companion marker | What it adds |
|---|---|
| AST | Paired enzyme that helps show whether muscle or mitochondrial injury is contributing |
| GGT | Sensitive to alcohol intake, certain medications and bile duct irritation |
| Alkaline phosphatase | Points toward bile flow obstruction or bone turnover rather than hepatocyte leakage |
| Bilirubin | Reflects the liver's ability to process and excrete haem breakdown products |
| Albumin and prothrombin time | Reflect synthetic function, which is what the liver is actually producing |
| Platelet count | A falling count over years can accompany advancing liver scarring |
| Triglycerides and HDL | Map the metabolic load that often accompanies liver fat |
| Fasting insulin and HbA1c | Show insulin resistance, a common driver behind a drifting enzyme value |
| Ferritin and iron studies | Screen for iron overload as an alternative explanation |
| Creatine kinase | Settles the question of a muscle source quickly |
Viral hepatitis serology, coeliac antibodies and thyroid markers are added when the history points that way, and imaging such as ultrasound or elastography is the usual next layer when a metabolic liver picture is suspected. A clinician decides which of those are appropriate.
Yes, meaningfully. Men generally run higher values than women, which is why some laboratories publish sex-specific ranges and why a result near the ceiling means something slightly different depending on whose report it is. Children have their own age-specific ranges, and paediatric studies of this enzyme in acute illness and after cardiac surgery illustrate how different the interpretive context is in that population[7][8].
Body composition matters more than body weight. Muscle mass contributes a small share of circulating enzyme, while visceral fat is the component most consistently associated with higher values. That is why two people at the same weight can sit at opposite ends of the range.
Being lean does not exempt anyone. Research in lean polycystic ovary syndrome examined associations between alanine aminotransferase and other biochemical parameters, including markers of insulin handling, in women who were not overweight[10]. The broader lesson is that metabolic load is not visible from the outside, which is the argument for measuring rather than assuming.
Addressing the driver, because the enzyme is a readout rather than the problem. If metabolic fat accumulation is the likely context, the interventions usually discussed first are unglamorous.
Reducing visceral fat through a sustained calorie deficit is associated with improvements in liver fat and liver enzymes. Both aerobic training and resistance training are associated with reductions in liver fat, including in people whose weight changes little. Lowering alcohol intake, reducing refined carbohydrate and added sugar intake, improving sleep and treating untreated sleep apnoea all plausibly contribute. Coffee intake is often asked about here, and any link with lower liver enzyme values is uncertain and interesting rather than prescriptive.
Medication and supplement review belongs in this list and belongs with a clinician. Some prescriptions raise enzyme values benignly and are continued, others warrant monitoring or a change, and that judgement is not one to make from a web page. Where a prescription treatment is being considered, including medications used in weight and metabolic management such as GLP-1 receptor agonists, a licensed provider evaluates whether it is appropriate for you. Experimental or clinician-gated interventions, including peptides, are exactly that, experimental and clinician-gated.
Time horizons are worth setting honestly. Liver enzyme values often respond over weeks to months rather than days, and a single reassuring repeat does not close the subject if the underlying driver has not changed.
When the number is markedly outside the standard range, when it is rising on repeat testing, or when symptoms accompany it. Jaundice, dark urine, pale stools, persistent right upper abdominal pain, unusual bruising or bleeding, marked and unexplained fatigue, swelling of the abdomen or legs, or confusion all warrant prompt medical attention regardless of what any lab value says.
Other situations that deserve a conversation sooner rather than later include a new or recently changed medication, known or possible exposure to hepatitis viruses, a family history of liver disease or iron overload, pregnancy, and any result that your own doctor has flagged. Discuss your results and any treatment with a clinician or licensed provider before acting on them.
Equally, a mildly raised value with no symptoms is not a reason to panic. It is a reason to repeat the test properly, run the companions that narrow the field, and take the pattern to someone who can see the whole picture.
If you want the detail on individual markers, there are dedicated reference pages for ALT, ast, ggt, alkaline phosphatase and triglycerides, and the Metabolic + Insulin panel groups the metabolic markers that most often travel with a drifting liver enzyme.
An ALT blood test measures alanine aminotransferase, a liver enzyme, in your serum. It is usually part of a liver panel or a comprehensive metabolic panel. The result reflects how much enzyme is leaking from liver cells, so it signals cellular stress rather than naming a specific diagnosis. Interpretation needs context from other markers.
The ALT on a blood test is alanine aminotransferase, an enzyme concentrated in liver cells and reported in units per litre. Typical lab reference ranges run roughly 7 to 56 U/L, though ranges vary by lab, age and sex. A single value is a snapshot, so the trend and context matter more than one reading.
ALT on a blood test stands for alanine aminotransferase, the enzyme that older reports label SGPT. It transfers amino groups between alanine and alpha-ketoglutarate inside cells. Because the enzyme normally stays inside the cell, blood levels rise when liver cells are stressed, injured or turning over faster than usual.
The ALT blood test is a liver enzyme test, usually ordered inside a liver panel or comprehensive metabolic panel alongside AST, alkaline phosphatase, GGT, bilirubin and albumin. It is sensitive to liver cell stress but not specific to one cause, so clinicians read it together with the other enzymes and your history.
Yes. SGPT stands for serum glutamic pyruvic transaminase, the older name for the enzyme now called alanine aminotransferase, or ALT. Same analyte, same units, no conversion needed. Many labs print ALT (SGPT) so readers comparing older and newer reports do not assume a different test was run.
Anything above the upper limit printed on your own report counts as outside the standard range, commonly around 56 U/L. Size matters for interpretation. Mild elevations are often linked to metabolic, alcohol, medication or exercise factors, while large elevations suggest more acute liver cell injury and are worth discussing with a clinician promptly.
Yes. Skeletal muscle contains this enzyme, so unaccustomed heavy resistance training, long downhill running or a return to training after a break can raise the value without any liver problem. Measuring creatine kinase alongside it usually clarifies the source. Avoiding heavy training for several days before a draw gives a cleaner reading.
Fasting is not required for this enzyme specifically. It is almost always drawn inside a wider panel, though, and tests sitting beside it such as glucose, fasting insulin and triglycerides usually do require fasting. Follow the instruction on your requisition, and keep the conditions consistent between tests for comparable results.
A low result is usually not treated as abnormal, because the test is designed to detect leakage upward. Very low values are sometimes discussed in relation to vitamin B6 status, since the enzyme needs pyridoxal phosphate, and to low muscle mass in older adults. Those are observational associations worth raising with a clinician in context.